

## Bios



### **Jeffrey P. Gold, M.D.**

Jeffrey P. Gold, M.D., is a nationally recognized leader and tireless advocate for transforming academic medicine and health care delivery. He became the eighth chancellor of the University of Nebraska Medical Center on Feb. 1, 2014. He also chairs the board of UNMC's principal clinical care system partner, Nebraska Medicine.

In April 2017, Dr. Gold was named interim chancellor of the University of Nebraska at Omaha. In December 2018, the University of Nebraska Board of Regents appointed Dr. Gold as UNO's full-time chancellor through June 30, 2022.

As UNMC's chief executive officer, Dr. Gold is responsible for all aspects of campus administration, including its annual operating budget of more than \$740 million, a staff of about 5,000 and its 3,900 students. Additionally, Nebraska Medicine has over 6,500 employees and an operating budget of well more than \$1.5 billion.

Dr. Gold holds a health professions academic appointment in the College of Medicine and in the College of Public Health. He serves as a University of Nebraska system vice president.

Prior to joining UNMC, Dr. Gold served as chancellor of the University of Toledo's health science campus, which includes the Colleges of Medicine, Nursing, Pharmacy, Health Science and Human Service, and Graduate Studies. In that role, Dr. Gold had full leadership responsibility of the clinical, education and research programs, the faculty practice plan and the clinical delivery system. As dean of the University of Toledo's College of Medicine and Life Sciences, Dr. Gold was responsible for the cultivation and recruitment of faculty, development and implementation of its curriculum and ensuring the highest level of education for its students, residents and faculty.

Prior to joining the University of Toledo, Dr. Gold served in academic and clinical leadership roles at the Albert Einstein College of Medicine and the Weill Cornell College of Medicine.

Dr. Gold graduated from the Cornell University College of Engineering, where he majored in theoretical and applied mechanics. He earned his M.D. from the Weill Cornell College of Medicine and completed his general surgery residency at The New York – Presbyterian Hospital and Memorial Sloan Kettering Hospital, where he later served as the administrative chief resident. He completed his cardiothoracic fellowship training at the Brigham and Women's Hospital and the Boston Children's Hospital of Harvard Medical School. Dr. Gold is certified by the American Board of Thoracic Surgery and specializes in adult and pediatric cardiac surgery.

Dr. Gold's service has included more than 50 national professional committees and more than 100 national organizations, volunteer boards, government/public health councils, and industry. He has served as chair of the American Medical Association's Council on Medical Education and has served as president of the Thoracic Surgery Directors Association, a national organization devoted to improving the education of resident physicians. Dr. Gold has served on the board of the Accreditation Council on Graduate Medical Education (ACGME) since 2012. He is currently serving a two-year term as chair of the ACGME with his term ending in September 2020. He also has held national leadership positions in the American Medical Association and other prestigious organizations.

He has been recognized as a Top 50 Health Care Executive and as a Top 100 Physician Executive, as well many awards for service leading numerous community volunteer programs, philanthropic campaigns and programs. He continues his research interests actively and continues to serve on several journal editorial boards. Dr. Gold has authored over 200 peer-reviewed articles, 250 national presentations, 40 books and chapters and over 60 invited professorships and keynote presentations.

He is married to a physician and has two adult children, currently residing in New York and Chicago.



### **Howard Gendelman, M.D.**

Dr. Howard Gendelman is the Margaret R. Larson Professor of Internal Medicine and Infectious Diseases, chairman of the Department of Pharmacology and Experimental Neuroscience, and director of the Center for Neurodegenerative Disorders at the University of Nebraska Medical Center.

Dr. Gendelman is credited in unraveling how functional alterations in brain immunity induce metabolic changes and ultimately lead to neural cell damage for a broad range of infectious, metabolic and neurodegenerative disorders. These discoveries have had broad implications in developmental therapeutics aimed at preventing, slowing or reversing neural maladies. He also is credited for the demonstration that AIDS dementia is a reversible metabolic encephalopathy; a finding realized at UNMC. His work has led to novel immunotherapy and nanomedicine strategies for Parkinson's and viral diseases being tested in early clinical trials as a result of intense translational investigations.

Dr. Gendelman obtained a bachelor's degree in natural sciences and Russian studies with honors from Muhlenberg College and his M.D. from the Pennsylvania State University-Hershey Medical Center, where he was the 1999 Distinguished Alumnus. He completed a residency in internal medicine at Montefiore Hospital, Albert Einstein College of Medicine and was a clinical and research fellow in neurology and infectious diseases at the Johns Hopkins University Medical Center.

He occupied senior faculty and research positions at Johns Hopkins, the National Institute of Allergy and Infectious Diseases, the Uniformed Services University of the Health Sciences Center, the Walter Reed Army Institute of Research, and the Henry Jackson Foundation for the Advancement in Military Medicine before joining the UNMC faculty in March 1993. He retired from the U.S. Army with the rank of lieutenant colonel.

Dr. Gendelman has authored over 400 peer-reviewed publications, edited nine books and monographs, holds eight patents, is the editor-in-chief and founder of the *Journal of Neuroimmune Pharmacology* along with service on numerous editorial boards, national and international scientific review and federal and state committees.

He has been an invited lecturer to more than 200 scientific seminars and symposia and the recipient of numerous local, national and international honors. These, include, but are not limited to, the Henry L. Moses Award in Basic Science; the Carter-Wallace Fellow for Distinction in AIDS Research; the David T. Purtilo Distinguished Chair of Pathology and Microbiology; the UNMC Scientist Laureate; University of Nebraska Outstanding Research and Creativity Award; 2013 UNMC Innovator of the Year; the 2014 Outstanding Faculty Mentor of Graduate Students; and the Joseph Wybran Distinguished Scientist Award.

Dr. Gendelman was named a J. William Fulbright Research Scholar at the Weizmann Institute of Science in Israel. In 2001, he received the prestigious Jacob Javits Neuroscience Research Award from the National Institute of Neurological Disorders and Stroke and the Career Research Award in Medicine from the UNMC Department of Internal Medicine.

He is included among a selective scientific group listed on [highlycited.com](http://highlycited.com) as one of the top cited scientists in his field. Dr. Gendelman has trained more than 40 scientists (students and postdoctoral fellows) who have themselves developed independent successful careers. Under his leadership, the department now holds scores of independent R01s or equivalent grants, four program project grants, and shares two program developmental awards.

His leadership is credited with the growth of the UNMC Department of Pharmacology and Experimental Neuroscience to be ranked among the top 10 nationwide among like federally funded departments; a particularly noteworthy feat as its position was 89 when he assumed leadership of the department.



### **Kamel Khalili, Ph.D.**

Kamel Khalili, Ph.D., is an internationally recognized neurovirologist and AIDS researcher. He received his Ph.D. from the University of Pennsylvania and completed a postdoctoral fellowship at the Wistar Institute in Philadelphia. He was the recipient of a prestigious Fogarty Scholarship from the National Cancer Institute at the NIH.

Dr. Khalili began his academic career as an assistant professor in the Department of Biochemistry and Molecular Biology at the Thomas Jefferson University in Philadelphia in 1987. In 1990, he was promoted to the rank of associate professor and established the Molecular Neurovirology Section.

Dr. Khalili joined the faculty of the former MCP\*Hahnemann School of Medicine (currently Drexel University College of Medicine) at the rank of professor, where he established the Center for NeuroVirology and NeuroOncology. In 1999, Dr. Khalili established the Center for Neurovirology and Cancer Biology at Temple University.

Currently, he is the Laura H. Carnell Professor and Chair (founding chair, 2005) of Neuroscience at the Lewis Katz School of Medicine at Temple University and director of the Center for Neurovirology. He is also director of the Comprehensive NeuroAIDS Center, an NIH-funded (P30 mechanism) multidisciplinary center that provides research infrastructure to the HIV-1/AIDS research community at Temple and other researchers in Philadelphia. This project is in its eighth year of funding.

Dr. Khalili has been studying the neuropathogenesis of viruses, most notably HIV-1 and JCV (John Cunningham virus), for more than 30 years. In the earlier years of the HIV-1/AIDS pandemic, Dr. Khalili's work led to several contributions on understanding the neuropathogenesis of AIDS. Since then, he has made several novel and important discoveries about how HIV-1 alters normal brain function and his laboratory studies have identified several pathways that can suppress viral infection.

More recently, he has led a team of scientists in his department to develop the CRISPR/Cas9 technology, a gene editing strategy, to successfully eradicate HIV-1 in human cell cultures and animal models, which is the first step in a cure for AIDS. In addition, his technology has shown promising results for protecting cells from HIV-1 infection. This same technology has been utilized to eradicate herpes simplex virus and JC virus from cell culture models as well. These findings were among the top 100 scientific discoveries of 2014 named by *Discovery* magazine.

Dr. Khalili has published more than 450 scientific papers in high quality, peer-reviewed journals, he has edited two textbooks related to viral oncology and human polyomaviruses, and has received more than \$70 million in funding from the NIH during his career, and currently ranks eighth on the Blue Ridge Institute for Medical Research list of funding among neuroscientists.

Dr. Khalili has mentored more than 95 students (including Ph.D. and M.D./Ph.D.) and postdoctoral fellows in his laboratory over the past 30 years. He is the founder of the International Society of NeuroVirology and the editor-in-chief of the *Journal of NeuroVirology*.

He has been the recipient of numerous awards for his scientific contributions, including the highly prestigious Pioneer in Neurovirology Award (2010), a Lifetime Achievement Award in 2013 from Temple University School of Medicine; the Contribution of Research to Humanity from the High Tech for Peace Foundation (Lugano, Switzerland) in 2016, and the Wybran Award for Extraordinary Contributions to the Advancement of the Fields of Neuroimmunology, Drugs of Abuse, and Immunity to Infections from the Society for Neuroimmune Pharmacology (2017), and the President's Award for Outstanding Achievement in Translational Research from Temple University (2017).



**Michael Dixon, Ph.D.**

Dr. Michael Dixon is president and CEO of the UNeMed Corporation, a company that works with faculty, students and staff of the University of Nebraska Medical Center (UNMC), the University of Nebraska at Omaha (UNO) and Nebraska Medicine to help commercialize innovative, new ideas that have the potential to improve public health for Nebraska residents and beyond. Dr. Dixon and the UNeMed staff work to match industry, entrepreneurs and investors with university researchers to foster partnerships for the commercial development of new technology.

Dr. Dixon's tenure at UNMC began in 1998 when he joined the Eppley Institute for Research in Cancer and Allied Diseases. Dr. Dixon's research interests at UNMC were focused in the areas of molecular biology, genetics, and biochemistry. In 2003, a move that transitioned him from the bench to the business side of science, Dr. Dixon joined the UNMC technology transfer office and began working with researchers to protect and develop new technology.

As president and CEO of UNeMed, Dr. Dixon is responsible for setting UNeMed's strategic path and directing UNeMed's activities; including efforts to protect, market, and license new technology. Under his leadership, UNeMed has more than doubled the number of new inventions and licenses it executes each year. In addition, UNeMed revenues have increased 10-fold.

Dr. Dixon is a graduate of Leadership Omaha Class 32 and a 2011 recipient of the Midlands Business Journal "40 under 40" award. As an active member of the community, Dr. Dixon serves on several boards, including Invest Nebraska, a non-profit, venture development organization that advises and invests in companies and early stage business ideas in Nebraska, and Bio Nebraska, a nonprofit trade association dedicated to the development and growth of Nebraska's bioscience industry.